UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Clinical cancer research, 2011-05, Vol.17 (9), p.2734-2743

2011

Volltextzugriff (PDF)

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Blood, 2007-11, Vol.110 (9), p.3281-3290

2007

Volltextzugriff (PDF)

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Blood, 2009-10, Vol.114 (16), p.3439-3447

2009

Volltextzugriff (PDF)

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6383-6391

2007

Volltextzugriff (PDF)

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Journal of medicinal chemistry, 2009-05, Vol.52 (9), p.3028-3038

2009

Volltextzugriff (PDF)

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

Bioorganic & medicinal chemistry letters, 2004-12, Vol.14 (24), p.6017-6021

2004

Volltextzugriff (PDF)

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

Bioorganic & medicinal chemistry letters, 2004-01, Vol.14 (2), p.549-552

2004

Volltextzugriff (PDF)

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Volltextzugriff (PDF)

Synthesis of conformationally restricted substance P antagonists

Bioorganic & medicinal chemistry letters, 1995-01, Vol.5 (2), p.111-114

1995

Volltextzugriff (PDF)

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

Blood, 2006-11, Vol.108 (11), p.4392-4392

2006

Volltextzugriff (PDF)

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

Blood, 2006-11, Vol.108 (11), p.4398-4398

2006

Volltextzugriff (PDF)

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

Blood, 2006-11, Vol.108 (11), p.3461-3461

2006

Volltextzugriff (PDF)

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.1576-1576

2005

Volltextzugriff (PDF)

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171

Blood, 2005-11, Vol.106 (11), p.1588-1588

2005

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome

Blood, 2005-11, Vol.106 (11), p.609-609

2005

Volltextzugriff (PDF)

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Volltextzugriff (PDF)

Synthesis of 3 H‐ and 14 C‐labelled CP‐88,059: A potent atypical antipsychotic agent

Journal of labelled compounds & radiopharmaceuticals, 1994-02, Vol.34 (2), p.117-125

1994

Volltextzugriff (PDF)

Synthesis of 3H- and 14C-labelled CP-88,059: A potent atypical antipsychotic agent

Journal of labelled compounds & radiopharmaceuticals, 1994-02, Vol.34 (2), p.117-125

1994

Volltextzugriff (PDF)

Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models

mBio, 2024-02, Vol.15 (2), p.e0299823-e0299823

2024

Volltextzugriff (PDF)

Human Cytomegalovirus Gene Expression during Infection of Primary Hematopoietic Progenitor Cells: A Model for Latency

Proceedings of the National Academy of Sciences - PNAS, 2002-12, Vol.99 (25), p.16255-16260

2002

Volltextzugriff (PDF)

Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

Kidney international reports, 2020-10, Vol.5 (10), p.1679-1689

2020

Volltextzugriff (PDF)

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

Blood, 2005-11, Vol.106 (11), p.1575-1575

2005

Volltextzugriff (PDF)

Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency

Blood, 2004-11, Vol.104 (11), p.1703-1703

2004

Volltextzugriff (PDF)

Novel inhibitors of fatty acid oxidation as potential metabolic modulators

Bioorganic & medicinal chemistry letters, 2004-02, Vol.14 (4), p.973-977

2004

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(10)
Biological And Medical Sciences
(9)
Humans
(9)
Medical Sciences
(9)
Animals
(8)
Pharmacology. Drug Treatments
(8)
Chemistry
(5)
Chemistry, Medicinal
(5)
Pharmacology & Pharmacy
(5)
Rats
(5)
Antineoplastic Agents
(4)
Chemistry, Organic
(4)
Oligopeptides - Pharmacology
(4)
Physical Sciences
(4)
Proteasome Inhibitors
(4)
Structure-Activity Relationship
(4)
Antineoplastic Agents - Pharmacology
(3)
Bortezomib
(3)
Mice
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Synthesis of conformationally restricted substance P antagonists

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Synthesis of 3 H‐ and 14 C‐labelled CP‐88,059: A potent atypical antipsychotic agent

Synthesis of 3H- and 14C-labelled CP-88,059: A potent atypical antipsychotic agent

Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models

Human Cytomegalovirus Gene Expression during Infection of Primary Hematopoietic Progenitor Cells: A Model for Latency

Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency

Novel inhibitors of fatty acid oxidation as potential metabolic modulators

Suchergebnisse filtern